Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis

Authors :: Elisa Muscianisi
Kristina Navrazhina
Sandra Garcet
Patricia C. Lee
Andrew Blauvelt
James G. Krueger
Dedee F. Murrell
Source :: The Journal of Allergy and Clinical Immunology, Journal of Allergy and Clinical Immunology
Publication Year :: 2020
Publisher :: The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology., 2020.
Abstract: Capsule summary (33 of 35 words; 2 of 2 sentences): Secukinumab reduced the inflammation and the expression of ACE2, which encodes the SARS-CoV-2 receptor, in plaques of patients with psoriasis. Reductions in ACE2 expression with secukinumab significantly correlated with reductions in disease activity.

Tools